10-K: Alphatec Holdings Reports 25% Revenue Growth in 2025

Alphatec Holdings, Inc. announced a 25% increase in total revenue to $764.2 million for the fiscal year ended December 31, 2025, driven by surgeon adoption and product portfolio expansion.

Summary

• Total revenue for the year ended December 31, 2025, was $764.2 million, an increase of 25% compared to $611.6 million in 2024.
• Surgical volume grew 22% and average revenue per surgery expanded 4% in 2025 compared to 2024.
• The net loss for 2025 was $(143.4) million, an improvement from a net loss of $(162.1) million in 2024.
• Operating activities provided net cash of $45.2 million in 2025, a significant turnaround from cash used in operating activities of $(44.7) million in 2024.
• The company issued $405.0 million principal amount of 0.75% Senior Convertible Notes due 2030 in March 2025, with net proceeds of approximately $392.9 million.
• 80% of the 2026 convertible notes were repurchased for approximately $268.4 million.
• Cash and cash equivalents stood at $160.8 million as of December 31, 2025, up from $138.8 million at December 31, 2024.
• Litigation-related expenses increased by $14.0 million, or 143%, to $23.8 million in 2025, primarily due to a settlement and ongoing matters.
• Interest expense, net, increased by $21.0 million, or 85%, to $45.9 million in 2025, driven by additional debt and amortization of debt discount.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong revenue and surgical volume growth, and a significant improvement in cash flow from operations. However, the company continues to incur net losses and faces increasing litigation and interest expenses, alongside intense market competition.

Positives

• Total revenue increased by $152.6 million, or 25%, to $764.2 million for the year ended December 31, 2025.
• Surgical volume grew 22% and average revenue per surgery expanded 4% in 2025, indicating strong market adoption and product value.
• Net loss improved to $(143.4) million in 2025 from $(162.1) million in 2024, showing progress towards profitability.
• Operating activities generated positive cash flow of $45.2 million in 2025, a significant reversal from negative cash flows in prior years.
• The surgeon user base grew 20% in 2025, driven by the ATEC Experience educational program.
• Cybersecurity systems, supporting infrastructure, and EOS products received HITRUST e1 certification in 2025, demonstrating robust security measures.
• High employee satisfaction was reported, with over 79% of respondents in a December 2025 survey willing to recommend the company as a desirable place to work, and low undesired turnover of approximately 5% for 2025.
• Successful nascent international footprint building in Australia, New Zealand, and Japan, with the first LTP surgery completed in Japan in late 2024.

Negatives

• The company continues to incur net losses, with an accumulated deficit of $1.4 billion as of December 31, 2025.
• Litigation-related expenses increased significantly by 143% to $23.8 million in 2025, primarily due to a litigation settlement and ongoing matters.
• Interest expense, net, increased by 85% to $45.9 million in 2025, reflecting higher debt levels and associated costs.
• A loss on debt extinguishment of $17.6 million was recorded in 2025 due to the repurchase of 80% of the 2026 convertible notes.
• Investing activities used $53.4 million in cash in 2025, primarily for the purchase of surgical instruments to support business growth and new product launches.

Risks

• Operating in a highly competitive market segment against large, well-established medical device companies with significant resources.
• Reliance on sales agents, with potential difficulties in recruiting or retaining qualified independent sales agents.
• Demand for products and pricing depend on adequate third-party coverage and reimbursement, which may be denied or reduced.
• Risk of manufacturing delays or product recalls if the company or its suppliers fail to comply with applicable regulations.
• Failure to timely obtain governmental clearances or approvals for future products or modifications could delay commercialization.
• Need to convince the spine surgeon community of product superiority and provide proper training for product acceptance.
• Business plan relies on assumptions about market trends that, if incorrect, may adversely affect growth and profitability.
• Dependence on senior management, sales and marketing team, engineering team, and key surgeon advisors, with the loss of any potentially harming the business.
• Reliance on a limited number of third-party manufacturers and a single supplier (Invibio for PEEK) for key raw materials, posing supply interruption risks.
• Consolidation in the healthcare industry could lead to price concessions or exclusion from some markets.
• Business is dependent upon the effective operation of information systems; security breaches, data loss, or other disruptions could compromise sensitive information or expose to liability.
• International operations are subject to risks including currency fluctuations, political/economic conditions, governmental pricing directives, and trade restrictions.
• A significant percentage of revenues are derived from sales of systems that include polyaxial pedicle screws (38% in 2025), making the business vulnerable to a decline in sales of these systems.
• Reliance on third-party licenses related to polyaxial pedicle screw systems, with risks of termination or disputes.
• Subject to federal and state healthcare fraud and abuse laws, health information privacy and security, and disclosure laws, with potential for substantial penalties for non-compliance.
• Failure to properly manage anticipated growth could place significant demands on managerial, operational, and financial resources.
• Nearly all operations are conducted in locations at risk of damage from fire, earthquakes, or other natural disasters.
• Public health crises, political crises, and other catastrophic events or events outside of control may impact the business.
• Tariffs and other trade measures could adversely affect the business, results of operations, financial position, and cash flows.
• Inability to successfully complete or integrate acquisitions of new and complementary businesses, products, or technologies.
• Use of artificial intelligence (AI) technology by employees or business partners could result in misuse or loss of proprietary information, violation of laws, or damage to reputation.
• Alphatec Holdings is a holding company with no operations, relying on dividends or other payments from subsidiaries to fulfill cash obligations.
• Potential product liability claims, including those related to biologics products, could exceed insurance coverage.
• Claims relating to improper handling, storage, or disposal of biological, hazardous, and radioactive materials could be costly.
• Inadequate protection of patents and other intellectual property rights could lead to market share loss to competitors.
• Risk of patent and other intellectual property litigation, which could be costly and divert management's attention.
• Need to raise additional funds in the future, which may not be available on acceptable terms, leading to dilution or relinquishing valuable rights.
• History of net losses and expectation to continue incurring net losses in the near future.
• Quarterly financial results could fluctuate significantly due to various factors.
• Covenants in loan documents and indentures may restrict business and operations, with non-compliance potentially leading to default.
• Stock price may fluctuate significantly, particularly if holders of substantial amounts of stock attempt to sell.
• Risk of becoming involved in securities class action litigation.
• Securities analysts may not provide coverage of common stock or may issue negative reports.
• Executive officers, directors, and principal stockholders (beneficially owning approximately 20% of outstanding common stock) can exert control over significant corporate decisions.
• Anti-takeover provisions in organizational documents and change of control provisions in agreements may discourage or prevent a change of control.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes (Sections 382 and 383 of the Internal Revenue Code).
• Subject to changes in tax rates, new tax legislation, or additional tax liabilities.

Future Outlook

The company anticipates continued success driven by increasing surgeon adoption of its approach-specific procedures and intends to pioneer spine innovation to improve surgical outcomes, fueling ongoing growth in surgical volume and revenue per surgery. Surgeon utilization is expected to increase through cultivated relationships and training. Significant development is underway to integrate and interconnect InformatiX technologies, with unprecedented functionalities expected to launch in 2026 and beyond. The company also plans to launch procedure-specific positioners for other procedures. While current liquidity is believed to be sufficient for at least 12 months, the company expects to continue incurring net losses in the near future and may need to raise additional funds.

Management Comments

• "Our future success will continue to be fueled by increasing surgeon adoption of our approach-specific procedures."
• "Our vision is to be the standard bearer in spine. By creating clinically distinct procedures that improve surgical outcomes, we believe that we are well positioned to continue to earn increasing share of the U.S. spine market, becoming the partner of choice for spine surgeons, hospitals, healthcare systems, and payors."
• "We intend to continue to pioneer spine innovation that improves surgical outcomes, fueling continued growth in surgical volume and revenue per surgery."
• "We expect surgeon utilization to continue to increase as we cultivate relationships, partnering with our customers in an increasing number of surgeries and fostering training to inspire partnership in increasingly complex surgeries."
• "We believe the opportunity to expand our strategic sales network is vast and expect to continue to compel sales professionals to sell through the clinical distinction and surgeon adoption that power our growth leadership."
• "We believe that our existing funds, cash generated from our operations and our existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure, debt service requirements and other business initiatives we plan to strategically pursue."

Industry Context

StockSavvy.ai notes that Alphatec Holdings operates in the highly competitive medical technology sector, specifically spine surgery, which is characterized by rapid technological change and significant competition from established players like Medtronic and Johnson & Johnson. The company's focus on "clinical distinction" and integrated procedural solutions, such as the InformatiX platform and approach-specific technologies, aims to differentiate it in a market where outcomes have historically been less predictable. The continued investment in R&D and surgeon education is crucial for market share expansion against larger, more resourced competitors. The company's strong revenue growth and positive operating cash flow suggest effective execution of its differentiation strategy within this challenging environment.

Comparison to Industry Standards

• Published research indicates that outcomes in spine surgery have historically been less predictable and less durable than those observed in many other orthopedic specialties, particularly with respect to reproducibility, long-term durability, and consistency across patient populations. Alphatec's procedural offerings are designed to address these limitations by advancing decompression, stabilization, and alignment.
• The company states its lateral franchise boasts "unparalleled optionality" and is "earning surgeons confidence and loyalty," which, if substantiated by independent data, would position it favorably against competitors like Medtronic (Sofamor Danek), Johnson & Johnson (DePuy Spine), and Globus Medical, who are noted as having substantially greater financial resources and more established distribution networks.

Corporate Governance

Legal Proceedings

• Litigation-related expenses increased by $14.0 million, or 143%, to $23.8 million for the year ended December 31, 2025, primarily due to a litigation settlement during the year and ongoing litigation matters.
• In May 2025, the company entered into a settlement with a shareholder to resolve a legal dispute.
• An ongoing lawsuit filed by NuVasive, Inc. in October 2017 against Mr. Miles (Chairman and CEO), with the company added as a defendant in June 2018. The Delaware Court ordered NuVasive to advance legal fees for Mr. Miles' defense.

Related Party Transactions

• The company purchased inventory totaling $12.0 million from Squadron Supplier Affiliate for the year ended December 31, 2025.
• David Pelizzon, President and Director of Squadron Capital, LLC, serves on the Company's Board of Directors.
• As of December 31, 2025, the company had $2.6 million due to the Squadron Supplier Affiliate.

Stakeholder Impact

• Shareholders: Experience potential dilution from future equity raises and the impact of stock price volatility. Executive officers, directors, and principal stockholders collectively own approximately 20% of outstanding common stock, allowing them to significantly influence corporate decisions. Anti-takeover provisions in organizational documents may discourage or prevent acquisitions.
• Employees: Benefit from competitive, performance-based compensation and benefits, opportunities for discounted equity ownership, recognition programs, and career development. The company reported high employee satisfaction (over 79% would recommend) and low undesired turnover (5% for 2025). A salary conversion plan for executives aligns their incentives with equity performance.
• Customers (Surgeons, Hospitals, Healthcare Systems, Payors): Benefit from improved surgical outcomes through clinically distinct procedures, an expanding product portfolio, enhanced training and education (ATEC Experience), and predictable surgical support. However, they may be impacted by third-party reimbursement policies.
• Suppliers: The company's reliance on third-party manufacturers and limited/single source suppliers (e.g., Invibio for PEEK) creates dependency. The company has inventory purchase commitments, with $5.0 million remaining as of December 31, 2025.
• Creditors: Hold significant debt obligations, including the Braidwell Term Loan ($200.0 million), Revolving Credit Facility ($15.0 million), 2026 Notes ($63.3 million), and 2030 Notes ($405.0 million). Covenants in loan documents and indentures could restrict business operations, and non-compliance could lead to default.

Next Steps

• Continue to invest in the development and launch of approaches and technologies intended to revolutionize spine surgery.
• Pioneer spine innovation that improves surgical outcomes, fueling continued growth in surgical volume and revenue per surgery.
• Cultivate surgeon relationships and foster training to inspire partnership in increasingly complex surgeries, aiming for continued increase in surgeon utilization.
• Add clinically astute and exclusive independent sales agents and direct sales representatives to expand the strategic sales network and penetrate existing accounts.
• Continue significant development to integrate and interconnect InformatiX technologies and bring unprecedented functionalities to market in 2026 and beyond.
• Plan to launch procedure-specific positioners for other procedures in the future.
• Monitor current spending and cash use, as well as the ability to secure additional credit facilities, term loans, or other similar arrangements.

Key Dates

Recommendation

Alphatec Holdings demonstrates strong operational momentum with significant revenue and surgical volume growth, coupled with a positive shift in operating cash flow. The strategic focus on clinical distinction and surgeon adoption appears to be yielding results. However, the company remains unprofitable, carries substantial debt, and faces increasing litigation costs. While the trajectory is positive, the inherent risks in a highly competitive and regulated industry, along with the need for future capital, suggest a "Hold" recommendation until a clear path to sustained profitability and debt reduction is more evident.

Keywords

Spine surgery, Medical technology, Spinal implants, InformatiX platform, EOS imaging, Neuromonitoring, Surgical planning, ATEC, Orthopedics, Healthcare, FDA regulation, Corporate governance, Financial performance, 10-K, PTP, LTP, Biologics